Long-Term PRRT for Neuroendocrine Tumors in Japan: Efficacy and Safety Confirmed
Peptide receptor radionuclide therapy (PRRT) with 177Lu-oxodotreotide showed long-term efficacy and acceptable safety in Japanese NET patients, confirming global PRRT results in the Japanese population.
Quick Facts
What This Study Found
177Lu-oxodotreotide PRRT: long-term efficacy and acceptable safety confirmed in Japanese NET patients, consistent with global PRRT data.
Key Numbers
How They Did This
Long-term efficacy and safety assessment of PRRT with 177Lu-oxodotreotide in Japanese NET patients.
Why This Research Matters
Japanese patients need local long-term safety data for treatment confidence. This confirms PRRT's role in NET management in Japan.
The Bigger Picture
PRRT represents the most successful clinical application of peptide-targeted radionuclide therapy worldwide.
What This Study Doesn't Tell Us
Japanese population-specific data. Sample size in full paper.
Questions This Raises
- ?How does Japanese PRRT response compare to Western populations?
- ?Should PRRT be first-line or reserved for advanced NETs in Japan?
- ?Would combination PRRT + chemotherapy improve Japanese NET outcomes?
Trust & Context
- Key Stat:
- Japan confirms PRRT Long-term Japanese data confirms that peptide-targeted radiation therapy (PRRT) effectively controls neuroendocrine tumors with acceptable safety
- Evidence Grade:
- Long-term efficacy/safety study in Japanese population.
- Study Age:
- Published in 2025.
- Original Title:
- Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.
- Published In:
- Annals of nuclear medicine (2026)
- Authors:
- Kobayashi, Noritoshi(2), Ono, Hiroaki, Okubo, Naoki, Akahoshi, Keiichi, Kudo, Atsushi, Ban, Daisuke, Ichikawa, Yasushi
- Database ID:
- RPEP-15446
Evidence Hierarchy
Frequently Asked Questions
What is PRRT?
Peptide receptor radionuclide therapy attaches radioactive atoms to peptides that target neuroendocrine tumor cells, delivering radiation directly to the cancer while sparing healthy tissue.
Does PRRT work for Japanese patients?
Yes. This long-term study confirmed PRRT is effective and safe in Japanese NET patients, consistent with results seen worldwide.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15446APA
Kobayashi, Noritoshi; Ono, Hiroaki; Okubo, Naoki; Akahoshi, Keiichi; Kudo, Atsushi; Ban, Daisuke; Ichikawa, Yasushi. (2026). Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.. Annals of nuclear medicine. https://doi.org/10.1007/s12149-026-02169-1
MLA
Kobayashi, Noritoshi, et al. "Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.." Annals of nuclear medicine, 2026. https://doi.org/10.1007/s12149-026-02169-1
RethinkPeptides
RethinkPeptides Research Database. "Long-term efficacy and safety of peptide receptor radionucli..." RPEP-15446. Retrieved from https://rethinkpeptides.com/research/kobayashi-2026-longterm-efficacy-and-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.